Medicare Enrolled

Dr. Vera Kleynberg, M.D.

Hematology & Oncology · Los Angeles, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
6221 WILSHIRE BLVD, Los Angeles, CA 90048
3239659995
In practice since 2006 (19 years)
NPI: 1568428324 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kleynberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kleynberg? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kleynberg

Dr. Vera Kleynberg is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kleynberg performed 828 Medicare services across 202 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kleynberg received a total of $11,357 from 75 pharmaceutical and/or device companies across 568 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kleynberg is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 828 Medicare services $11,357 industry payments

Medicare Practice Summary

Medicare Utilization ↗
828
Medicare services
Bottom 46% in CA for hematology & oncology
202
Unique beneficiaries
$75
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~44 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
349 $90 $171
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
163 $100 $161
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
161 $5 $5
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
107 $66 $112
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
48 $145 $312
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$11,357
Total received (2018-2024)
Avg $1,622/year across 7 years
Top 30% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
75
Companies
568
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,346 (99.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$748
2023
$1,364
2022
$2,253
2021
$2,920
2020
$1,630
2019
$1,752
2018
$690

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$236
E.R. Squibb & Sons, L.L.C.
$56
PharmaEssentia USA Corporation
$47
Novartis Pharmaceuticals Corporation
$45
Daiichi Sankyo Inc.
$43
Celgene Corporation
$39
PFIZER INC.
$37
JAZZ PHARMACEUTICALS INC.
$33
Ipsen Biopharmaceuticals, Inc
$30
Janssen Pharmaceuticals, Inc
$27
Genmab U.S., Inc.
$26
TerSera Therapeutics LLC
$25
SOBI, INC
$24
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Bayer Healthcare Pharmaceuticals Inc.
$20
Incyte Corporation
$19
Stemline Therapeutics Inc.
$18
Top 3 companies account for 45.2% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,795
Incyte Corporation
$1,318
Amgen Inc.
$832
Janssen Biotech, Inc.
$731
PFIZER INC.
$708
AstraZeneca Pharmaceuticals LP
$494
Merck Sharp & Dohme Corporation
$399
Novartis Pharmaceuticals Corporation
$390
CTI BioPharma Corp.
$208
TerSera Therapeutics LLC
$187
GENZYME CORPORATION
$186
Seattle Genetics, Inc.
$185
Eisai Inc.
$169
Genentech USA, Inc.
$167
Karyopharm Therapeutics Inc.
$164
Gilead Sciences, Inc.
$149
GlaxoSmithKline, LLC.
$146
Bayer Healthcare Pharmaceuticals Inc.
$140
Bayer HealthCare Pharmaceuticals Inc.
$135
Takeda Pharmaceuticals U.S.A., Inc.
$126
Kite Pharma, Inc.
$123
Seagen Inc.
$122
PharmaEssentia USA Corporation
$111
Ipsen Biopharmaceuticals, Inc
$102
Dova Pharmaceuticals
$98
Octapharma USA, Inc.
$96
Shionogi Inc
$95
Lilly USA, LLC
$93
Teva Pharmaceuticals USA, Inc.
$92
Celgene Corporation
$88
JAZZ PHARMACEUTICALS INC.
$86
EISAI INC.
$80
PUMA BIOTECHNOLOGY, INC.
$80
Daiichi Sankyo Inc.
$79
Alexion Pharmaceuticals, Inc.
$75
Genmab U.S., Inc.
$73
GE HEALTHCARE
$70
Merck Sharp & Dohme LLC
$61
Global Blood Therapeutics, Inc.
$61
Mylan Institutional Inc.
$60
Exelixis Inc.
$58
Stemline Therapeutics Inc.
$58
ADC Therapeutics America, Inc.
$55
Myriad Genetic Laboratories, Inc.
$54
EMD Serono, Inc.
$53
Puma Biotechnology, Inc.
$49
Jazz Pharmaceuticals Inc.
$46
Taiho Oncology, Inc.
$44
Janssen Pharmaceuticals, Inc
$44
Coherus Biosciences Inc.
$37
Sirtex Medical Inc
$35
EUSA Pharma (US) LLC
$29
Novocure Inc.
$27
Clinigen Inc
$27
SOBI, INC
$24
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Chiesi USA, Inc.
$23
Helsinn Therapeutics (U.S.), Inc.
$22
Progenics Pharmaceuticals, Inc.
$21
Organon LLC
$20
Spectrum Pharmaceuticals Inc.
$19
Sobi, Inc
$18
Amneal Pharmaceuticals LLC
$18
Cumberland Pharmaceuticals, Inc.
$18
Mirati Therapeutics, Inc.
$16
Rigel Pharmaceuticals, Inc.
$16
Dendreon Pharmaceuticals LLC
$16
ARRAY BIOPHARMA INC
$15
Pharmacyclics LLC, An AbbVie Company
$15
Alnylam Pharmaceuticals Inc.
$15
AbbVie, Inc.
$15
Emmaus Medical, Inc.
$14
Acrotech Biopharma LLC
$14
Verastem, Inc.
$14
Secura Bio, Inc.
$12
Top 3 companies account for 34.7% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AVASTIN · Alecensa · BALVERSA · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Balversa · Bavencio · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Endari · Enhertu · Epkinly · FARYDAK · FERRIPROX · Fabhalta · Fulphila · GAMIFANT · GIVLAARI · HEMADY · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · MYCHOICE CDX · Mulpleta · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · Oncology · Onivyde · Orserdu · PANZYGA · PEMAZYRE · PIQRAY · PROMACTA · PROVENGE · PYLARIFY · Proleukin · Quzyttir · REBLOZYL · RETACRIT · ROLVEDON · RYBREVANT · Revlimid · SANCUSO · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · Tavalisse · Trodelvy · Udenyca · VENCLEXTA · VYXEOS · Vectibix · Venclexta · Vonjo · XALKORI · XARELTO · XPOVIO · Xermelo · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Los Angeles?
Compare hematology & oncology specialists in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
395
Per 100K population
4.0
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Kleynberg is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Kleynberg experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Kleynberg performed 349 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kleynberg receive payments from pharmaceutical companies?
Yes. Dr. Kleynberg received a total of $11,357 from 75 companies across 568 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kleynberg's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Kleynberg's average Medicare payment per service is $75. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kleynberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →